GSK plc Sponsored ADR (GSK)
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK plc (GSK) TD Cowen 45th Annual Health Care Conference (Transcript)
GSK plc (NYSE:GSK ) TD Cowen 45th Annual Health Care Conference March 3, 2024 9:50 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have GSK at the TD Cowen Conference once again this year.
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
On Monday, the Food and Drug Administration (FDA) accepted for review GSK plc's GSK marketing application for depemokimab in two indications.
GSK abandons diversity targets following Trump pressure
British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's opposition to them.
Canada purchases 500,000 doses of GSK's vaccine for bird flu
The Public Health Agency of Canada said on Wednesday it has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most at risk.
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the fourth quarter of 2024, more than tripling year-on-year. While sales of the HIV therapy called Cabenuva also did not disappoint, totaling $396 million, up 23.8% quarter-on-quarter.
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin 's hedge fund Citadel has placed a £305 million ($390 million) short bet against GSK PLC GSK, marking the largest wager against the UK pharma giant in over a decade, reported the Financial Times.
GSK meningitis jab bags approval by FDA
GSK PLC has bagged approval for its Penmenvy meningitis vaccine by the US Food and Drug Administration. Designed to target five major serogroups of meningitis-causing Neisseria meningitidis bacteria, GSK on Monday said the jab had been green lit for 10 to 25 year olds.
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration (FDA) approved GSK's combination vaccine to protect against meningococcal infection for use in individuals aged 10 through 25 years, the company said on Saturday.
Hedge Fund Citadel takes short position in GSK, FT reports
Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on Friday.
